51980-60-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-METHOXY-ETHOXY)-PHENOL is used as a reactant for the preparation of (2-?fluoro-?4-?methanesulfonylphenyl)?-?6-?[4-?(3-?isopropyl-?[1,?2,?4]?oxadiazol-?5-?yl)?-?piperidin-?1-?yl]?-?5-?nitro-?pyrimidin-?4-?yl?-?amine, an oral agonist of orphan G-protein coupled receptor 119. This application is significant as it contributes to the development of new drugs targeting specific receptors, potentially leading to novel treatments for various medical conditions.

Upstream product

• 109-86-4 2-methoxy-ethanol 
• 123-31-9 hydroquinone 
• 17178-10-8 2-methoxy-ethyl p-toluenesulfonyloxy ester 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 6482-24-2 2-Bromoethyl methyl ether 

Downstream Products

• 266682-86-4 C₉H₁₁Cl₂O₄P 
• 872314-71-1 1-(2-bromo-5-chlorobenzyloxy)-4-(2-methoxyethoxy)benzene 
• 266682-90-0 C₁₃H₁₉ClNO₆P 
• 1054579-06-4 C₂₁H₂₆N₄O₇ 
• 1237534-54-1 2,5-bis[4-(2-methoxyethoxy)phenyloxycarbonyl]styrene 
• 1439936-20-5 2-bromo-1-{4-(4-(2-methoxyethoxy)phenoxy)-2,6-dimethylphenyl}ethanone 
• 1439936-21-6 4-{4-(4-(2-methoxyethoxy)phenoxy)-2,6-dimethylphenyl}thiazol-2-amine 
• 1439936-18-1 N-(4-{4-(4-(2-methoxyethoxy)phenoxy)-2,6-dimethylphenyl}thiazol-2-yl)isonicotinamide 
• 1439936-44-3 2-fluoro-N-(4-{4-(4-(2-methoxyethoxy)phenoxy)-2,6-dimethylphenyl}thiazol-2-yl)isonicotinamide 
• 1439936-19-2 1-{4-(4-(2-methoxyethoxy)phenoxy)-2,6-dimethylphenyl}ethanone 
• 39255-23-7 1-Bromo-4-(2-Methoxyethoxy)-benzene 
• 359014-85-0 2-(2-{2-[4-(2-Methoxyethoxy)phenoxy]ethoxy}ethoxy)ethanol 

Relevant academic research and scientific papers

Pyridine salt / 1,4-dihydropyridine derivative and preparation method thereof

The present invention discloses a pyridine salt / 1,4-dihydropyridine derivative (NAD / NADH analog) with novel structure. The NAD / NADH analog can substitute natural NAD / NADH to be applied to a biochemical system for redox reactions, and can also be used as an electron carrier for the energy transfer of an enzymatic fuel cell. Further, the NAD / NADH analogs provided by the invention are easy to prepare, isolate and purify, and have a high yield.

IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases

Mesogen-jacketed liquid crystalline polymers substituted with oligo(oxyethylene) as peripheral chain

Mesogen-jacketed liquid crystalline polymer (MJLCP) is a typical rod-shaped macromolecule. Its unique molecular architecture allows one to tune the geometric parameters of the macromolecular rod. Moreover, the rod surface chemistry can be controlled by de

Self-assembly and dynamics of [2]- and [3]rotaxanes with a dinuclear macrocycle containing reversible Os-N coordinate bonds

With a dinuclear macrocycle 2 that contains weak reversible OsVI-N coordinate bonds, self-assembly and equilibrium dynamics of [2]- and [3]rotaxanes have been investigated. When the macrocycle 2 was mixed together with threads 4a-e, which all contain an adipamide station but different sizes of end groups, [2]pseudorotaxane- and rotaxane-like complexes were immediately formed with large association constants > of 7 × 103M-1 in CDCl3 at 298 K. Exchange dynamics, explored by 2D-EXSY experiments, suggest that assembly and disassembly of complexes occur through two distinct pathways, slipping or clipping, and this depends on the size of the end groups. The slipping pathway is predominant with smaller end groups that give pseudorotaxane-like complexes, while the clipping pathway is observed with larger end groups that yield rotaxane-like complexes. Under the same conditions, exchange barriers (ΔG≠) were 14.3 kcal mol-1 for 4a and 16.7 kcal mol-1 for 4d, and indicate that the slipping process is at least one order of magnitude faster than the clipping process. Using threads 13a and 13b that contain two adipamide groups, more complicated systems have been investigated in which [2]rotaxane, [3]rotaxane, and free components are in equilibrium. Concentration- and temperature-dependent 1H NMR spectroscopic studies allowed the identification of all possible elements and the determination of their relative distributions in solution. For example, the relative distribution of the free components, [2]rotaxane, and [3]rotaxane are 30, 45, and 25%, respectively, in a mixture of 2 (2mM) and 13a (2mM) in CDCl3, at 10°C. However, [3]rotaxane exists nearly quantitatively in a mixture of 2 (4mM) and 13a (2mM) in CDCl3 at a low temperature - 10°C.

Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs

A range of polyether para-substituted phosphoramidates were synthesised and found to have substantially elevated aqueous solubilities compared to the underivatised parent prodrug. A 30-fold increase in aqueous solubility could be achieved without a substantial decrease of in vitro activity against HIV-1. Replacement of the aryl (i.e. phenolic) moiety by tyrosine led to a substantial enhancement in aqueous solubility but also to a decrease in antiviral potency. A previously unobserved trend was identified, relating increased aryl substituent steric bulk to decreased antiviral activity. (C) 2000 Elsevier Science Ltd. All rights reserved.